

Patrick Mallia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5147174/publications.pdf>

Version: 2024-02-01

70
papers

6,569
citations

94433

37
h-index

98798

67
g-index

73
all docs

73
docs citations

73
times ranked

7520
citing authors

#	ARTICLE	IF	CITATIONS
1	Infective Exacerbations of Chronic Lung Disease. , 2022, , 259-265.		0
2	Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial. Thorax, 2022, 77, 950-959.	5.6	7
3	Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary disease. Journal of Clinical Investigation, 2022, 132, .	8.2	27
4	Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. Journal of Allergy and Clinical Immunology, 2021, 147, 510-519.e5.	2.9	121
5	Symptomatic, biochemical and radiographic recovery in patients with COVID-19. BMJ Open Respiratory Research, 2021, 8, e000908.	3.0	10
6	Asthma and viruses: A focus on rhinoviruses and SARS-CoV-2. Journal of Allergy and Clinical Immunology, 2021, 147, 1648-1651.	2.9	5
7	Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections. Journal of Experimental Pharmacology, 2021, Volume 13, 645-659.	3.2	17
8	Innate-like Gene Expression of Lung-Resident Memory CD8 ⁺ T Cells during Experimental Human Influenza: A Clinical Study. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 826-841.	5.6	16
9	Human rhinovirus infection and COPD: role in exacerbations and potential for therapeutic targets. Expert Review of Respiratory Medicine, 2020, 14, 777-789.	2.5	7
10	Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPD. Journal of Allergy and Clinical Immunology, 2020, 146, 840-850.e7.	2.9	8
11	Targeted Retreatment of Incompletely Recovered Chronic Obstructive Pulmonary Disease Exacerbations with Ciprofloxacin. A Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase III Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 549-557.	5.6	9
12	In vivo experimental models of infection and disease. , 2019, , 195-238.		1
13	Validity of the diagnosis of pneumonia in hospitalised patients with COPD. ERJ Open Research, 2019, 5, 00031-2019.	2.6	14
14	Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Science Translational Medicine, 2019, 11, .	12.4	75
15	Antiviral immunity is impaired in COPD patients with frequent exacerbations. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L893-L903.	2.9	57
16	<p>Inflammation and infections in unreported chronic obstructive pulmonary disease exacerbations</p>. International Journal of COPD, 2019, Volume 14, 823-833.	2.3	13
17	Lesson of the month 2: A case of nitrous oxide-induced pancytopenia. Clinical Medicine, 2019, 19, 129-130.	1.9	9
18	Human Rhinovirus Impairs the Innate Immune Response to Bacteria in Alveolar Macrophages in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1496-1507.	5.6	42

#	ARTICLE	IF	CITATIONS
19	Modulating airway glucose to reduce respiratory infections. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 121-124.	2.5	4
20	Bronchial mucosal IFN- β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 114-125.e4.	2.9	65
21	Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection. <i>Journal of Clinical Investigation</i> , 2019, 130, 523-538.	8.2	42
22	Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 815-823.e6.	2.9	63
23	Comparative Metabolomic Sampling of Upper and Lower Airways by Four Different Methods to Identify Biochemicals That May Support Bacterial Growth. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 432.	3.9	18
24	Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. <i>Nature Communications</i> , 2018, 9, 2229.	12.8	153
25	A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN- β and IFN- γ) and Type 2 Inflammation (IL-5 and IL-13). <i>EBioMedicine</i> , 2017, 19, 128-138.	6.1	102
26	Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro. <i>Antiviral Research</i> , 2017, 137, 93-101.	4.1	123
27	Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthma. <i>PLoS ONE</i> , 2017, 12, e0183864.	2.5	7
28	Reduced sputum expression of interferon-stimulated genes in severe COPD. <i>International Journal of COPD</i> , 2016, Volume 11, 1485-1494.	2.3	16
29	Azithromycin for Acute Exacerbations of Asthma. <i>JAMA Internal Medicine</i> , 2016, 176, 1630.	5.1	89
30	Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD. <i>Chest</i> , 2016, 149, 62-73.	0.8	70
31	The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 158-174.	2.6	144
32	The MIF Antagonist ISO-1 Attenuates Corticosteroid-Insensitive Inflammation and Airways Hyperresponsiveness in an Ozone-Induced Model of COPD. <i>PLoS ONE</i> , 2016, 11, e0146102.	2.5	43
33	A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA) Tj ETQq1 1 0.784314 rgBZ /Overlo		
34	Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms. <i>EBioMedicine</i> , 2015, 2, 64-70.	6.1	24
35	Interleukin-18 Is Associated With Protection Against Rhinovirus-Induced Colds and Asthma Exacerbations. <i>Clinical Infectious Diseases</i> , 2015, 60, 1528-1531.	5.8	19
36	The influence of asthma control on the severity of virus-induced asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 497-500.e3.	2.9	42

#	ARTICLE	IF	CITATIONS
37	Pathogenesis of Viral Infection in Exacerbations of Airway Disease. <i>Annals of the American Thoracic Society</i> , 2015, 12, S115-S132.	3.2	76
38	Lower airway colonization and inflammatory response in COPD: a focus on <i>Haemophilus influenzae</i> . <i>International Journal of COPD</i> , 2014, 9, 1119.	2.3	41
39	Experimental rhinovirus infection in COPD: Implications for antiviral therapies. <i>Antiviral Research</i> , 2014, 102, 95-105.	4.1	25
40	IL-33-Dependent Type 2 Inflammation during Rhinovirus-induced Asthma Exacerbations <i>In Vivo</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1373-1382.	5.6	500
41	The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease—A systematic review. <i>Journal of Clinical Virology</i> , 2014, 61, 181-188.	3.1	89
42	The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 906-913.	5.6	453
43	Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. <i>Lancet Respiratory Medicine</i> , 2014, 2, 919-932.	10.7	68
44	Tolerogenic signaling by pulmonary CD1c+ dendritic cells induces regulatory T cells in patients with chronic obstructive pulmonary disease by IL-27/IL-10/inducible costimulator ligand. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 944-954.e8.	2.9	37
45	Lymphocyte subsets in experimental rhinovirus infection in chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2014, 108, 78-85.	2.9	19
46	Bronchial platelet-activating factor receptor in chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2014, 108, 898-904.	2.9	13
47	Soluble Major Histocompatibility Complex Class I-Related Chain B Molecules Are Increased and Correlate With Clinical Outcomes During Rhinovirus Infection in Healthy Subjects. <i>Chest</i> , 2014, 146, 32-40.	0.8	3
48	Airway Inflammation and Illness Severity in Response to Experimental Rhinovirus Infection in Asthma. <i>Chest</i> , 2014, 145, 1219-1229.	0.8	80
49	Neutrophil adhesion molecules in experimental rhinovirus infection in COPD. <i>Respiratory Research</i> , 2013, 14, 72.	3.6	23
50	Outgrowth of the Bacterial Airway Microbiome after Rhinovirus Exacerbation of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1224-1231.	5.6	329
51	Rhinovirus Infection Induces Degradation of Antimicrobial Peptides and Secondary Bacterial Infection in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1117-1124.	5.6	238
52	Defining critical roles for NF- κ B p65 and type I interferon in innate immunity to rhinovirus. <i>EMBO Molecular Medicine</i> , 2012, 4, 1244-1260.	6.9	80
53	Viruses exacerbating chronic pulmonary disease: the role of immune modulation. <i>BMC Medicine</i> , 2012, 10, 27.	5.5	67
54	Rhinovirus 16-induced IFN- λ 1 and IFN- λ 2 are deficient in bronchoalveolar lavage cells in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1506-1514.e6.	2.9	190

#	ARTICLE	IF	CITATIONS
55	Lung microbiology and exacerbations in COPD. <i>International Journal of COPD</i> , 2012, 7, 555.	2.3	101
56	Immunological pathways in virus-induced COPD exacerbations: a role for IL-15. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1010-1015.	3.4	9
57	Asthma exacerbations: Origin, effect, and prevention. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1165-1174.	2.9	301
58	RSV-Induced Bronchial Epithelial Cell PD-L1 Expression Inhibits CD8+ T Cell Nonspecific Antiviral Activity. <i>Journal of Infectious Diseases</i> , 2011, 203, 85-94.	4.0	66
59	Experimental Rhinovirus Infection as a Human Model of Chronic Obstructive Pulmonary Disease Exacerbation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 734-742.	5.6	349
60	The Role of IL-15 Deficiency in the Pathogenesis of Virus-Induced Asthma Exacerbations. <i>PLoS Pathogens</i> , 2011, 7, e1002114.	4.7	58
61	New Paradigms in the Pathogenesis of Chronic Obstructive Pulmonary Disease II. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 532-534.	3.5	58
62	Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13562-13567.	7.1	447
63	Respiratory Syncytial Virus Persistence in Chronic Obstructive Pulmonary Disease. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, S63-S70.	2.0	84
64	Models of infection and exacerbations in COPD. <i>Current Opinion in Pharmacology</i> , 2007, 7, 259-265.	3.5	9
65	Influenza infection and COPD. <i>International Journal of COPD</i> , 2007, 2, 55-64.	2.3	57
66	An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. <i>Respiratory Research</i> , 2006, 7, 116.	3.6	87
67	How Viral Infections Cause Exacerbation of Airway Diseases. <i>Chest</i> , 2006, 130, 1203-1210.	0.8	149
68	Role of deficient type III interferon- λ production in asthma exacerbations. <i>Nature Medicine</i> , 2006, 12, 1023-1026.	30.7	955
69	Mechanisms and Experimental Models of Chronic Obstructive Pulmonary Disease Exacerbations. <i>Proceedings of the American Thoracic Society</i> , 2005, 2, 361-366.	3.5	29
70	Viral infection. , 0 , 76-96.		2